Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review

By L. Hooper, Rachel L. Thompson, R. Harrison, C. Summerbell, A. Ness, Helen J. Moore, H. Worthington, P. Durrington, Julian P. T. Higgins, N. Capps and 3 more. British medical journal, 2006

783 citations recorded by the source corpus.

Subfields: Nutrition and Dietetics, Physiology, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/51ef41855cc55d6e48e259ecf2b3fad92a176e11

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Nutrition and Dietetics

1. D. Mozaffarian
2. I. Graham
3. E. Rimm

In Physiology

1. Rhian M. Touyz
2. Marja-Riitta Taskinen
3. I. Graham
4. E. Rimm
5. D. Mozaffarian
6. F. B. Hu

In Public Health, Environmental and Occupational Health

1. D. Mozaffarian
2. I. Graham
3. E. Rimm
4. F. B. Hu
5. Douglas G. Altman
6. W. Willett

Citations in the corpus

• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “The data remain inconclusive and the clinical efficacy of omega-3 fatty acids appears to be related to non-lipid effects.(330,331) Moreover, studies with omega-3 fatty acids have suffered from the dose used (1 g/day), which does not affect plasma lipids to a large extent, as the dose required to dec”
• Utilization of Volatile Fatty Acids from Microalgae for the Production of High Added Value Compounds (2017, background): “is the best candidate for production of biofuels, PUFAs and EPS [66].”
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “Although a recent Japanese study in patients with hypercholesterolaemia reported a 19% reduction in CVD outcome,(286) the data remain inconclusive and their clinical efficacy appears to be related to non-lipid effects.(287,288) Two randomized placebo-controlled trials [Reduction of Cardiovascular Ev”
• Fish intake, contaminants, and human health: evaluating the risks and the benefits. (2006, background): “04).(94) When we added additional placebo-controlled, double-blind, randomized trials(60-62) performed since 2003, marine n-3 PUFAs reduced total mortality by 17% (pooled relative risk, 0.”
• Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. (2018, background): “[DOI: 10.1002/14651858.CD003177.pub2] Hooper 2006 Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review.”
• Hypertriglyceridemia: its etiology, effects and treatment (2007, background): “, eicosapentaenoic and docosahexaenoic acid) are components of both the Mediterranean diet and of fish oils.(35) Daily consumption of 4 g of omega-3 fatty acids, along with with restricted energy and saturated-fat intakes, can reduce plasma triglyceride levels by as much as 20%.”